MGMT and glioblastoma: The median overall survival was 11.5 (95% CI: 3.71, 33.8) and 26.9 months (95% CI: 8.94-NR) while the 2-year survival rates were 33% (95% CI: 10.3%, 58.8%) and 60% (95% CI: 12.6%, 88.2%) for MGMT unmethylated and methylated GBM, respectively.